Nuvation Bio Inc.

NUVB · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders18.4%

Institutions68.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$62.90M	$7.87M	–	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	$7.08M	–	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	$795000	–	–
Gross profit as a percentage of revenue.	–	10.1%	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$213.06M	-$592.63M	-$93.32M	-$3.06M
Operating income as a percentage of revenue.	-338.7%	-7527.3%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$204.63M	-$567.94M	-$86.85M	-$3.05M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$-2.00	$-0.44	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$-2.00	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$164.09M	$35.72M	$132.42M	$908111
Everything the company owns that has value — cash, property, inventory, investments, and more.	$594.82M	$540.63M	$776.15M	–
All of the company's interest-bearing borrowings, short and long term combined.	$52.93M	$6.28M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$289.11M	$76.84M	$30.15M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$305.72M	$463.79M	$746.00M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$173.40M	-$130.40M	-$68.20M	-$700826
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$8.00M	–	–	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$181.40M	–	–	–

	You	Peer avg
P/E	–	14.2
Revenue Growth	+555.6%	+23.1%
ROE	-47.8%	-0.1%

Nuvation Bio Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison